“Sensitivity of KRAS-Mutated Non-Small Cell Lung Cancer to a Combination of MEK Kinase Inhibitor (Trametinib) and Autophagy Inhibitor (Hydroxychloroquine) in a Tissue Explant Model”. Voprosy onkologii 72, no. 1 (March 11, 2026): OF-2403. Accessed October 14, 2026. https://voprosyonkologii.ru/index.php/journal/article/view/1-26-Sensitivity-of-KRAS-Mutated.